Barclays Maintains Overweight on PTC Therapeutics, Raises Price Target to $122
Benzinga Newsdesk 2 months ago
NewsPrice TargetAnalyst Ratings
Barclays analyst Eliana Merle maintains PTC Therapeutics (NASDAQ:PTCT) with a Overweight and raises the price target from $120 to $122.
Barclays analyst Eliana Merle maintains PTC Therapeutics (NASDAQ:PTCT) with a Overweight and raises the price target from $120 to $122.